NEUROFIBROMA, PLEXIFORM
Clinical trials for NEUROFIBROMA, PLEXIFORM explained in plain language.
Never miss a new study
Get alerted when new NEUROFIBROMA, PLEXIFORM trials appear
Sign up with your email to follow new studies for NEUROFIBROMA, PLEXIFORM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug TURALIO takes on tough childhood cancers in early trial
Disease control Recruiting nowThis early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Koselugo under the microscope: Real-World data on nerve tumor drug
Disease control Recruiting nowThis study tracks how well the drug Koselugo (selumetinib) works and what side effects it causes in people with Neurofibromatosis Type 1 and painful nerve tumors. About 200 patients in South Korea will be followed during their normal doctor visits. The goal is to confirm the drug…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill hopes to shrink painful nerve tumors in NF1 patients
Disease control Recruiting nowThis early-stage trial tests a daily pill called PAS-004 in 56 adults with NF1 who have at least one symptomatic, inoperable plexiform neurofibroma. The study has two parts: Part A finds a safe dose, and Part B checks safety and whether the drug can shrink tumors. Participants ta…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC